Therapeutic Area

Type 2 Diabetes

Therapeutic area intelligence for Type 2 Diabetes with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Eli Lilly →

Assets

Edinburgh →

Foundayo →

Recent signals(3)

ClinicalJune 19, 2026

Edinburgh Study Investigates Pancreas Lipotoxicity and Weight Loss in Type 2 Diabetes

The Edinburgh Diabetes Remission Study aims to explore the role of fat accumulation in the pancreas and its impact on type 2 diabetes remission through weight loss.

CompetitiveJune 16, 2026

Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes

Phase 3 ACHIEVE results indicate Foundayo outperformed oral semaglutide and dapagliflozin in treating type 2 diabetes.

ClinicalJune 10, 2026

AI-Driven Nutrition Study for Type 2 Diabetes Shows Promise for Glycemic Control

The AIM-MET study is evaluating a microbiome-targeted nutritional product's effect on glycemic control in type 2 diabetes over 24 weeks.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Type 2 Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.